GlassScriptPhysician profile
Gary L Gross
NPI 1336143247
$9,897.46
in general payments reported to CMS, 2019-2025
41 companies · $1,114 in 2025
The $1,114 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,789 · 2020: $1,080 · 2021: $1,044 · 2022: $823 · 2023: $2,379 · 2024: $1,669 · 2025: $1,114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,963 · Travel and Lodging: $1,198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,962.93 |
| Travel and Lodging | $1,198.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,929.69 | 2019-2025 | Breztri, Airsupra, Tezspire |
| Glaxosmithkline, LLC. | $1,677.70 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Genzyme Corporation | $682.88 | 2019-2024 | |
| Csl Behring | $453.72 | 2019-2025 | Haegarda, Andembry, Hizentra |
| Novartis Pharmaceuticals Corporation | $396.35 | 2019-2025 | |
| Pfizer INC. | $367.03 | 2019-2025 | |
| Genentech USA, INC. | $362.44 | 2019-2025 | Xolair |
| Abbvie INC. | $341.24 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $253.49 | 2019-2025 | Dupixent |
| Pharming Healthcare, INC. | $231.65 | 2019-2025 | Ruconest |
| Takeda Pharmaceuticals U.S.A., INC. | $205.63 | 2020-2025 | Cuvitru, Hyqvia, Eohilia |
| Optinose US, INC. | $166.59 | 2019-2025 | |
| Biocryst US Sales Co., LLC | $165.18 | 2021-2025 | Orladeyo |
| Alk-Abello, INC | $155.98 | 2019-2022 | |
| Kaleo, INC. | $148.79 | 2019-2024 | Auvi-Q |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Gross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.